Clinical Trial Detail

NCT ID NCT02271139
Title Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
Recruitment No longer available
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

non-small cell lung carcinoma

Therapies

Alectinib

Age Groups: adult

Additional content available in CKB BOOST